Description: Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Home Page: www.exactsciences.com
EXAS Technical Analysis
5505 Endeavor Lane
Madison,
WI
53719
United States
Phone:
608 284 5700
Officers
Name | Title |
---|---|
Mr. Kevin T. Conroy | Chairman of The Board & CEO |
Mr. Jeffrey T. Elliott CFA | Exec. VP, CFO & COO |
Mr. D. Scott Coward | Chief Legal Officer |
Mr. Graham P. Lidgard | Emeritus Chief Science Officer |
Mr. Everett V. Cunningham | Chief Commercial Officer |
Dr. Jorge A. Garces Ph.D. | Chief Science Officer |
Mr. Sri Kalluri | Chief Information Officer |
Ms. Megan Jones | Associate Mang. of Investor Relations |
Mr. Tim Caprez | Chief Compliance Counsel & VP |
Mr. Vic Parker | Head of Sales |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 2.603 |
Price-to-Sales TTM: | 3.9532 |
IPO Date: | 2001-02-01 |
Fiscal Year End: | December |
Full Time Employees: | 6420 |